Pomalidomide

An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.

375 mg/m2 administered IV on day 1 (only for CD20+ tumors)

Background: * Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with human immunodeficiency virus (HIV) (PLWH) in the United States.

Background: Non-Hodgkin lymphoma (NHL) is the most common cancer among people living with HIV in the United States. People with HIV are up to 17 times more likely to get NHL than people who do not have HIV. The disease may also be different in these two groups. More study is needed for treating people with both HIV and NHL.

Objective: To test a study drug (pomalidomide) in combination with chemotherapy with or without another drug (rituximab) in people with HIV-associated NHL. Eligibility: Adults aged 18 years or older diagnosed with HIV-associated B-cell NHL with high-risk features. Design: Individuals will undergo screening. They will have a physical exam. They will have blood and urine tests and tests of heart function. They may have imaging scans.

Live record on ClinicalTrials.gov →

• Histologically or cytologically confirmed B-cell NHL confirmed by the Laboratory of Pathology (LP), NCI, with one or more of the following features:
• Leptomeningeal/CSF involvement
• High-risk for CNS relapse per CNS-IPI (score 4-6)
• Plasmablastic histology
• Gamma herpesvirus positive tumor
• Measurable or evaluable lymphoma.

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.